CLVS Clovis Oncology, Inc. Stock Quote

CLVS [NASD]

Index	-	P/E	-	EPS (ttm)	-2.11	Insider Own	0.40%	Shs Outstand	138.21M	Perf Week	-8.77%
Market Cap	99.96M	Forward P/E	-	EPS next Y	-0.83	Insider Trans	-14.24%	Shs Float	128.04M	Perf Month	-67.74%
Income	-258.40M	PEG	-	EPS next Q	-0.41	Inst Own	37.50%	Short Float	21.64%	Perf Quarter	-58.30%
Sales	145.00M	P/S	0.69	EPS this Y	47.70%	Inst Trans	-19.59%	Short Ratio	2.25	Perf Half Y	-79.57%
Book/sh	-2.19	P/B	-	EPS next Y	39.70%	ROA	-51.60%	Target Price	3.00	Perf Year	-86.24%
Cash/sh	0.87	P/C	0.82	EPS next 5Y	-	ROE	101.90%	52W Range	0.69 - 7.24	Perf YTD	-73.69%
Dividend	-	P/FCF	-	EPS past 5Y	24.10%	ROI	-67.70%	52W High	-90.15%	Beta	1.79
Dividend %	-	Quick Ratio	1.40	Sales past 5Y	353.00%	Gross Margin	73.40%	52W Low	2.62%	ATR	0.18
Employees	413	Current Ratio	1.50	Sales Q/Q	-10.20%	Oper. Margin	-	RSI (14)	25.39	Volatility	11.63% 14.19%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	31.50%	Profit Margin	-	Rel Volume	0.36	Prev Close	0.71
Shortable	Yes	LT Debt/Eq	-	Earnings	May 04 BMO	Payout	-	Avg Volume	12.33M	Price	0.71
Recom	3.20	SMA20	-50.09%	SMA50	-59.84%	SMA200	-76.47%	Volume	4,401,362	Change	-0.04%

May-06-22

Downgrade

H.C. Wainwright

Buy → Neutral

May-18-20

Reiterated

H.C. Wainwright

Buy

$29 → $33

Apr-27-20

Downgrade

SVB Leerink

Mkt Perform → Underperform

Apr-09-20

Downgrade

BofA/Merrill

Neutral → Underperform

Jan-08-20

Reiterated

H.C. Wainwright

Buy

$36 → $27

Nov-19-19

Downgrade

Evercore ISI

Outperform → In-line

Sep-24-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

$22 → $10

Aug-13-19

Downgrade

BofA/Merrill

Buy → Neutral

Aug-02-19

Downgrade

Guggenheim

Buy → Neutral

May-29-19

Downgrade

Goldman

Neutral → Sell

Apr-15-19

Reiterated

H.C. Wainwright

Buy

$39 → $37

Feb-13-19

Initiated

H.C. Wainwright

Buy

$40

Dec-04-18

Upgrade

Leerink Partners

Mkt Perform → Outperform

Oct-31-18

Downgrade

JP Morgan

Overweight → Neutral

Oct-19-18

Resumed

Piper Jaffray

Neutral

Sep-25-18

Initiated

Leerink Partners

Mkt Perform

Feb-22-18

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Feb-22-18

Upgrade

Evercore ISI

In-line → Outperform

Oct-23-17

Initiated

Barclays

Overweight

$105

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

$81

May-16-22 08:30AM	2 Biotech Stocks That Could Go Parabolic Motley Fool +6.10%
May-09-22 11:05AM	Alcon (ALC) to Report Q1 Earnings: What's in the Cards? Zacks -17.90%
May-06-22 01:23PM	Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results Zacks -32.56%
07:12AM	Why Clovis Oncology Stock Was Plummeting This Week Motley Fool
May-05-22 10:22AM	Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag Zacks -12.50%
08:00AM	Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference Business Wire
May-04-22 02:21PM	Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss Zacks -20.00%
09:15AM	Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs Business Wire
May-03-22 08:35AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-02-22 12:21PM	Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings? Zacks
10:01AM	DaVita (DVA) to Report Q1 Earnings: What's in the Offing? Zacks
Apr-28-22 08:00AM	Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting Business Wire
Apr-27-22 03:03PM	Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-20-22 08:00AM	Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4 Business Wire
Apr-18-22 04:51PM	Why Clovis Oncology Stock Fell 10.5% on Monday Motley Fool
Apr-08-22 02:54PM	Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition Benzinga
08:00AM	Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022 Business Wire
Apr-04-22 03:11PM	Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study Zacks +8.80%
Mar-31-22 05:06PM	These 10 Stocks Are Skyrocketing Today Insider Monkey +22.42%
04:41PM	Why Clovis Oncology Stock Skyrocketed 80% This Week Motley Fool
09:22AM	Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status Benzinga
08:01AM	Clovis Oncology to seek FDA approval for ovarian cancer drug as a maintenance therapy MarketWatch
06:00AM	Clovis Oncologys Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial Business Wire
Mar-25-22 11:30AM	Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report? Zacks
Mar-16-22 08:00AM	Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 Business Wire
Feb-26-22 06:34AM	Newsflash: Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Revenue Forecasts Simply Wall St.
Feb-25-22 08:00AM	Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting Business Wire
Feb-24-22 02:49PM	Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag Zacks +20.99%
Feb-23-22 08:05AM	Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones Business Wire
Feb-10-22 04:05PM	Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call Business Wire
Jan-19-22 10:15AM	2 Cancer Stocks With Absurdly Low Valuations Motley Fool
Jan-10-22 08:00AM	Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 Business Wire
Jan-03-22 10:07AM	Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? Zacks +15.87%
Dec-09-21 08:00AM	Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit Business Wire -7.91%
Dec-03-21 11:31AM	Why Is Clovis (CLVS) Down 32% Since Last Earnings Report? Zacks -11.25%
Nov-04-21 06:46AM	Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag Zacks
Nov-03-21 09:15AM	Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces Third Quarter 2021 Operating Results Business Wire
07:48AM	Shareholders in Clovis Oncology (NASDAQ:CLVS) are in the red if they invested five years ago Simply Wall St.
Oct-27-21 03:03PM	Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks -5.29%
Oct-20-21 08:00AM	Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3 Business Wire
Oct-19-21 08:00AM	Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement Business Wire
Oct-15-21 09:15AM	Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition Zacks
Oct-07-21 09:00AM	Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286 Business Wire
Sep-29-21 10:00AM	Can These Former Biotech Growth Stocks Regain Their Form? Motley Fool
Sep-20-21 08:00AM	Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program Business Wire -5.58%
Sep-03-21 11:31AM	Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound? Zacks -5.71%
Aug-27-21 11:37AM	Why Clovis Oncology Shares Got a Bump This Week Motley Fool
Aug-24-21 02:00AM	Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland Business Wire
Aug-16-21 04:21PM	Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program Business Wire
Aug-05-21 10:57AM	Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down Zacks
02:34AM	What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)? Simply Wall St.
Aug-04-21 09:15AM	Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces Second Quarter 2021 Operating Results Business Wire
Jul-28-21 03:03PM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-21-21 08:00AM	Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4 Business Wire
Jul-12-21 04:05PM	Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors Business Wire
Jun-28-21 07:00AM	Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine Business Wire -5.66%
Jun-23-21 07:00AM	Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment Business Wire
Jun-15-21 05:39AM	2 Great Reasons to Buy This Cancer Treatment Stock Now Motley Fool
Jun-12-21 06:49AM	Here's Why Wall Street Is Betting Against Clovis Oncology Motley Fool
Jun-10-21 04:30PM	Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders Business Wire -5.39%
Jun-09-21 11:00AM	Why Clovis Oncology Stock Is Rocketing Higher Today Motley Fool +10.51%
06:36AM	Geo, ContextLogic, Clovis Oncology Get Swept Up in Meme Stock Surge TheStreet.com
Jun-04-21 11:31AM	Clovis (CLVS) Down 5.3% Since Last Earnings Report: Can It Rebound? Zacks
May-19-21 06:27PM	Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting Business Wire
May-17-21 04:15PM	Clovis Oncology Announces At-The-Market Equity Offering Program Business Wire
May-07-21 03:09AM	If You Had Bought Clovis Oncology's (NASDAQ:CLVS) Shares Three Years Ago You Would Be Down 88% Simply Wall St.
May-06-21 10:39AM	Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales Zacks
May-05-21 10:04AM	Clovis Oncology Reports 11% Drop In Q1 Sales As COVID-19 Hit Rubraca Sales Benzinga +6.35%
09:15AM	Clovis Oncology (CLVS) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces First Quarter 2021 Operating Results Business Wire
06:45AM	Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 04:05PM	Clovis Oncology to Present at the Bank of America 2021 Health Care Conference Business Wire
12:33PM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-21-21 04:00PM	Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5 Business Wire +5.82%
Apr-10-21 08:30AM	Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021 Business Wire
Mar-25-21 11:30AM	Why Is Clovis (CLVS) Up 4.4% Since Last Earnings Report? Zacks
Mar-22-21 09:50AM	Return On Capital Employed Overview: Clovis Oncology Benzinga
08:34AM	Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock? Zacks
07:17AM	Clovis (CLVS) Stock Jumps 47.7%: Will It Continue to Soar? Zacks
Mar-19-21 04:30PM	Why Clovis Oncology Stock Skyrocketed Today Motley Fool +47.74%
11:13AM	Return On Capital Employed Overview: Clovis Oncology Benzinga
09:24AM	5 Top Stock Gainers for Friday: FedEx, Dollar General, Clovis TheStreet.com
08:19AM	Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint MarketWatch
08:00AM	Clovis Oncologys Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation Business Wire
06:50AM	Clovis Oncology Skyrockets on Ovarian Cancer Drug Success TheStreet.com
Mar-02-21 10:21AM	Understanding Clovis Oncology's Unusual Options Activity Benzinga -8.19%
Feb-23-21 09:24AM	Clovis Oncology: Q4 Earnings Insights Benzinga -10.03%
08:00AM	Clovis Oncology Announces 2020 Operating Results Business Wire
06:30AM	Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:14AM	Earnings Preview for Clovis Oncology Benzinga
Feb-17-21 08:00AM	Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23 Business Wire
Feb-11-21 08:00AM	Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting Business Wire -9.91%
Feb-06-21 02:41AM	Could The Clovis Oncology, Inc. (NASDAQ:CLVS) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-04-21 08:00AM	Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting Business Wire
Feb-02-21 10:00AM	Alexion (ALXN) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-11-21 08:00AM	Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020 Business Wire +11.29%
Dec-30-20 06:49AM	Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug Zacks +10.56%

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MUEHL DANIEL W	See Remarks	May 02	Sale	1.97	4,570	9,002	85,439	May 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	May 02	Sale	1.97	3,733	7,353	276,220	May 03 04:15 PM
Gross Paul Edward	See Remarks	May 02	Sale	1.97	4,570	9,002	79,393	May 03 04:15 PM
Rolfe Lindsey	See Remarks	May 02	Sale	1.97	4,252	8,376	98,327	May 03 04:15 PM
Harding Thomas C.	See Remarks	May 02	Sale	1.97	76	150	2,936	May 03 04:15 PM
Harding Thomas C.	See Remarks	May 02	Sale	1.97	1,700	3,349	12,429	May 03 04:15 PM
Harding Thomas C.	See Remarks	Apr 04	Sale	2.66	7	19	2,831	Apr 05 04:16 PM
Gross Paul Edward	See Remarks	Mar 02	Sale	1.87	10,706	19,977	66,444	Mar 03 04:15 PM
Rolfe Lindsey	See Remarks	Mar 02	Sale	1.87	10,945	20,423	86,817	Mar 03 04:15 PM
MUEHL DANIEL W	See Remarks	Mar 02	Sale	1.87	10,706	19,977	72,490	Mar 03 04:16 PM
Harding Thomas C.	See Remarks	Mar 02	Sale	1.87	880	1,642	1,662	Mar 03 04:15 PM
Harding Thomas C.	See Remarks	Mar 02	Sale	1.87	6,946	12,961	6,850	Mar 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Mar 02	Sale	1.87	10,770	20,097	264,308	Mar 03 04:15 PM
Rolfe Lindsey	See Remarks	Feb 02	Sale	1.94	4,514	8,756	84,357	Feb 03 04:17 PM
MUEHL DANIEL W	See Remarks	Feb 02	Sale	1.94	5,436	10,544	70,045	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Feb 02	Sale	1.94	81	157	1,652	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Feb 02	Sale	1.94	2,037	3,951	6,015	Feb 03 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Feb 02	Sale	1.94	4,442	8,616	261,802	Feb 03 04:16 PM
Gross Paul Edward	See Remarks	Feb 02	Sale	1.94	5,436	10,544	63,999	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Jan 03	Sale	2.75	7	19	1,551	Jan 04 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Dec 02	Sale	3.00	304	912	260,041	Dec 03 04:15 PM
Harding Thomas C.	See Remarks	Dec 02	Sale	3.00	7	21	1,542	Dec 03 04:15 PM
Harding Thomas C.	See Remarks	Dec 02	Sale	3.00	141	423	5,395	Dec 03 04:15 PM
MUEHL DANIEL W	See Remarks	Dec 02	Sale	3.00	248	744	67,403	Dec 03 04:16 PM
Rolfe Lindsey	See Remarks	Dec 02	Sale	3.00	346	1,038	82,628	Dec 03 04:16 PM
Gross Paul Edward	See Remarks	Dec 02	Sale	3.00	248	744	61,357	Dec 03 04:15 PM
Rolfe Lindsey	See Remarks	Nov 02	Sale	4.55	4,209	19,151	79,987	Nov 03 04:18 PM
IVERS-READ GILLIAN C	See Remarks	Nov 02	Sale	4.55	3,696	16,817	257,074	Nov 03 04:19 PM
Harding Thomas C.	See Remarks	Nov 02	Sale	4.55	62	282	1,531	Nov 03 04:15 PM
Harding Thomas C.	See Remarks	Nov 02	Sale	4.55	1,682	7,653	4,346	Nov 03 04:15 PM
MUEHL DANIEL W	See Remarks	Nov 02	Sale	4.55	4,523	20,580	64,505	Nov 03 04:15 PM
Gross Paul Edward	See Remarks	Nov 02	Sale	4.55	4,523	20,580	58,459	Nov 03 04:15 PM
Harding Thomas C.	See Remarks	Oct 04	Sale	4.41	6	26	1,412	Oct 05 04:31 PM
Harding Thomas C.	See Remarks	Sep 02	Sale	4.89	7	34	1,403	Sep 03 05:21 PM
Harding Thomas C.	See Remarks	Sep 02	Sale	4.89	141	689	3,563	Sep 03 05:21 PM
IVERS-READ GILLIAN C	See Remarks	Sep 02	Sale	4.89	304	1,487	254,980	Sep 03 04:15 PM
Rolfe Lindsey	See Remarks	Sep 02	Sale	4.89	347	1,697	78,122	Sep 03 04:15 PM
Gross Paul Edward	See Remarks	Sep 02	Sale	4.89	249	1,218	55,318	Sep 03 04:15 PM
MUEHL DANIEL W	See Remarks	Sep 02	Sale	4.89	249	1,218	61,364	Sep 03 04:16 PM
IVERS-READ GILLIAN C	See Remarks	Aug 03	Sale	4.82	3,683	17,752	252,005	Aug 03 09:40 PM
Harding Thomas C.	See Remarks	Aug 03	Sale	4.82	62	299	1,391	Aug 03 09:38 PM
Harding Thomas C.	See Remarks	Aug 03	Sale	4.82	1,678	8,088	2,511	Aug 03 09:38 PM
MUEHL DANIEL W	See Remarks	Aug 03	Sale	4.82	4,507	21,724	58,459	Aug 03 09:36 PM
Rolfe Lindsey	See Remarks	Aug 03	Sale	4.82	4,195	20,220	75,473	Aug 03 09:32 PM
Gross Paul Edward	See Remarks	Aug 03	Sale	4.82	4,507	21,724	52,413	Aug 03 09:31 PM
Harding Thomas C.	See Remarks	Jul 01	Sale	5.79	26	151	1,272	Jul 06 04:16 PM
Gross Paul Edward	See Remarks	Jun 03	Sale	5.63	231	1,301	49,262	Jun 03 07:03 PM
MUEHL DANIEL W	See Remarks	Jun 03	Sale	5.63	231	1,301	55,308	Jun 03 07:01 PM
Rolfe Lindsey	See Remarks	Jun 03	Sale	5.63	322	1,813	73,602	Jun 03 07:00 PM
IVERS-READ GILLIAN C	See Remarks	Jun 03	Sale	5.63	283	1,593	249,905	Jun 03 06:58 PM
Harding Thomas C.	See Remarks	Jun 03	Sale	5.63	7	39	1,235	Jun 03 06:57 PM
Harding Thomas C.	See Remarks	Jun 03	Sale	5.63	131	738	1,725	Jun 03 06:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience